TY - JOUR
T1 - In vitro antimicrobial activity of grepafloxacin and its therapeutic efficacy on respiratory infections
AU - Tateyama, Masao
AU - Fukuhara, Hiroshi
AU - Irabu, Yuei
AU - Inadome, Jun
AU - Gaja, Michihiro
AU - Saito, Atsushi
AU - Kusano, Nobuchika
AU - Furugen, Yoshiko
AU - Nakasone, Isamu
AU - Taira, Shinko
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1995
Y1 - 1995
N2 - We carried out laboratory and clinical studies on grepafloxacin (GPFX), a new oral pyridone carboxylic acid, antimicrobial drug. 1) Laboratory activity The minimum inhibitory concentrations (MICs) of GPFX for a total of 334 clinically isolated strains and 40 standard strains were determined and compared with those of tosufloxacin (TFLX), ofloxacin (0FLX), ciprofloxacin (CPFX), enoxacin (ENX), norfloxacin (NFLX), sparfloxacin (SPFX) and erythromycin (EM). GPFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci was the same as that of TFLX, and more potent than that of the other five reference quinolones. Against gram-negative bacilli except Legionella pneumophila, the in vitro activity of GPFX was the same or lower than that of TFLX, and more potent than that of the other drugs. The MIC90 of GPFX for clinical isolates of L. pneumophila was almost equal to that of SPFX, and superior to those of the other drugs. The MIC90 of GPFX for standard strains of Legionella spp. was slightly inferior to those of TFLX and SPFX, and the same as that of CPFX. 2) Clinical efficacy We administered GPFX to five patients with respiratory tract infection at a dose of 200~300 mg daily for 7 to 14 days. The clinical results were good in 5 cases, yielding an efficacy rate of 100%. In all cases, neither side effects nor abnormal laboratory findings were observed.
AB - We carried out laboratory and clinical studies on grepafloxacin (GPFX), a new oral pyridone carboxylic acid, antimicrobial drug. 1) Laboratory activity The minimum inhibitory concentrations (MICs) of GPFX for a total of 334 clinically isolated strains and 40 standard strains were determined and compared with those of tosufloxacin (TFLX), ofloxacin (0FLX), ciprofloxacin (CPFX), enoxacin (ENX), norfloxacin (NFLX), sparfloxacin (SPFX) and erythromycin (EM). GPFX proved to have a broad antibacterial spectrum, and its in vitro activity against gram-positive cocci was the same as that of TFLX, and more potent than that of the other five reference quinolones. Against gram-negative bacilli except Legionella pneumophila, the in vitro activity of GPFX was the same or lower than that of TFLX, and more potent than that of the other drugs. The MIC90 of GPFX for clinical isolates of L. pneumophila was almost equal to that of SPFX, and superior to those of the other drugs. The MIC90 of GPFX for standard strains of Legionella spp. was slightly inferior to those of TFLX and SPFX, and the same as that of CPFX. 2) Clinical efficacy We administered GPFX to five patients with respiratory tract infection at a dose of 200~300 mg daily for 7 to 14 days. The clinical results were good in 5 cases, yielding an efficacy rate of 100%. In all cases, neither side effects nor abnormal laboratory findings were observed.
KW - grepafloxacin
UR - http://www.scopus.com/inward/record.url?scp=0029131172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029131172&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1995.43.Supplement1_308
DO - 10.11250/chemotherapy1995.43.Supplement1_308
M3 - Article
AN - SCOPUS:0029131172
VL - 43
SP - 308
EP - 313
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
ER -